Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib in Relapsed Waldenström's Macroglobulinemia
NCT01813227Phase 2Completed
- Sponsor
- Hackensack Meridian Health
- Start
- Apr 2013
- Primary completion
- Sep 2014
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in Waldenström's macroglobulinemia (WM), sponsored by Hackensack Meridian Health. Primary endpoint: Overall Response Rate at 1 year. Started Apr 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01813227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813227.